Further investigation is required to determine the exact mechanisms by which Lp-PLA2 contributes to the development of cognitive impairment in PD, and whether Lp-PLA2 could be a potential therapeutic target for the treatment of cognitive impairment in PD. This evidence concerns the gene PLA2G7 and Parkinson disease.